Results for this period
Interim period (second quarter)1 October 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company made progress on research and development, including the biofoundry business contracted by NEDO and large-scale pipelines with domestic and overseas partner companies. Because the company receives many contracts related to national policy initiatives and net sales are concentrated in the fourth quarter, results fluctuate by quarter.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥240 million (YoY +0.1%) |
| Operating profit | ¥-186 million |
| Ordinary income | ¥-190 million |
| Profit attributable to owners of the parent | ¥-192 million |
| Net income per share | -¥16.93 |
| Equity ratio | End of the current fiscal period 59.7 / End of previous period 71 |
| Total assets | ¥3,205 million |
| Net assets | ¥1,913 million |
| Cash flows from operating activities | ¥293,136 thousand |
| Cash flows from investing activities | ¥-594,669 thousand |
| Cash flows from financing activities | ¥-106,808 thousand |
| Cash and cash equivalents at end of period | ¥1,651,199 thousand |
| Full-year earnings forecast | Net Sales ¥1,035 million (YoY -3.7%) / Operating profit ¥-356 million / Ordinary income ¥175 million (YoY +12.1%) / Net income ¥146 million (YoY +15.3%) |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥25,169 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 11,355,100 |
| Treasury Shares at Period-End | 36 |
| Factors Behind Changes in Business Performance | The company made progress on research and development, including the biofoundry business contracted by NEDO and large-scale pipelines with domestic and overseas partner companies. Because the company receives many contracts related to national policy initiatives and net sales are concentrated in the fourth quarter, results fluctuate by quarter. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that quarterly results fluctuate because it receives many contracts related to national policy initiatives, including NEDO-contracted projects, and net sales are concentrated in the fourth quarter. It did not specify the direct factors behind the increase in losses.